HBOT for Carbon Monoxide Poisoning: Emergency Protocols

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Studies on hyperbaric oxygen therapy (HBOT) for post-traumatic stress disorder (PTSD) have shown symptomatic improvements in 393 subjects across eight studies [https://pubmed.ncbi.nlm.nih.gov/388826688/].
HBOT treatment for PTSD involved 40-60 sessions (HBOTS) over a wide range of pressures, from 1.3 to 2.0 atmospheres absolute (ATA).
A systematic review found no statistically significant differences in NIHSS scores for acute ischaemic stroke patients treated with HBOT compared to control groups [https://pubmed.ncbi.nlm.nih.gov/38308217/].
For PTSD, HBOT showed a linear dose-response relationship, meaning more oxygen over time led to greater symptomatic improvement, with cumulative oxygen doses ranging from 1002 to 11,400 atmosphere-minutes of oxygen [https://pubmed.ncbi.nlm.nih.gov/388826688/].

Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized chamber, a method under investigation for various medical conditions. While the primary topic of this article is emergency protocols for carbon monoxide poisoning, the provided research focuses on other applications of HBOT, specifically for conditions like post-traumatic stress disorder (PTSD), acute ischaemic stroke (AIS), and traumatic brain injury (TBI). For PTSD, a systematic review of eight studies involving 393 subjects found that HBOT led to statistically significant symptomatic improvements. Patients received 40-60 HBOT sessions, with pressures between 1.3 and 2.0 ATA. These improvements were linked to a greater total oxygen dose, ranging from 1002 to 11,400 atmosphere-minutes of oxygen [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This suggests a measurable impact of HBOT on neurological symptoms, even if not directly related to carbon monoxide poisoning in the provided data. See the carbon monoxide poisoning evidence atlas for the full study-by-study evidence breakdown.

What is Hyperbaric Oxygen Therapy (HBOT)?

Hyperbaric oxygen therapy (HBOT) is a medical treatment where a person breathes 100% pure oxygen in a special chamber that is pressurized to a level higher than the normal air pressure. This increased pressure allows the lungs to gather much more oxygen than they would at normal air pressure. The extra oxygen is then carried throughout the body by the blood. This can help fight bacteria and stimulate the release of substances called growth factors and stem cells, which promote healing. HBOT is currently being studied for its potential to treat a variety of conditions, including those involving brain injury and neurological symptoms. The goal is to deliver more oxygen to tissues that are deprived of it, which can aid in recovery and reduce inflammation.

In our analysis, we see HBOT is being tested for different conditions. For instance, research indicates that HBOT can lead to symptom improvement in certain neurological conditions. This includes conditions like post-traumatic stress disorder (PTSD) and the lingering effects of traumatic brain injury (TBI). The fundamental principle behind HBOT is to super-saturate the body with oxygen, pushing it into areas that might not receive enough under normal circumstances. This high concentration of oxygen can support cellular function, reduce swelling, and promote the repair of damaged tissues. The chambers used for HBOT can be monoplace, designed for one person, or multiplace, which can treat several patients at once. The specific pressure and duration of each HBOT session are carefully controlled and tailored to the individual patient and the condition being treated.

How Pressure and Oxygen Work in HBOT

The effectiveness of HBOT comes from two main factors: increased pressure and increased oxygen concentration. When the chamber is pressurized, it increases the partial pressure of oxygen in the blood plasma. This means more oxygen dissolves directly into the fluid part of the blood, rather than just being carried by red blood cells. This dissolved oxygen can then reach areas of the body that might have poor blood flow or are otherwise difficult for red blood cells to access.

For example, in conditions where tissues are starved of oxygen, HBOT can provide a critical boost. The oxygen delivery helps to reduce inflammation and supports the body's natural healing processes. The precise dosage of oxygen and pressure is crucial for treatment outcomes. Studies have explored a wide range of pressures, from as low as 1.3 atmospheres absolute (ATA) to 2.0 ATA or higher, depending on the condition being addressed. The duration of each session and the total number of sessions also play a significant role in the overall therapeutic effect. These parameters are often determined by specific clinical protocols developed through research and trials.

The Role of HBOT in Neurological Recovery

In neurological conditions, HBOT aims to improve brain function by increasing oxygen supply to damaged or underperforming brain regions. This can help to reduce brain swelling, improve blood flow, and stimulate the growth of new blood vessels. The enhanced oxygenation can also support the metabolism of brain cells, helping them to recover and function more effectively.

For conditions like PTSD, where brain activity and structure may be altered by trauma, HBOT's ability to influence brain physiology is particularly relevant. The therapy can potentially modulate inflammatory responses in the brain and support neural repair mechanisms. This approach moves beyond simply addressing symptoms and aims to tackle underlying physiological issues that contribute to neurological dysfunction. The goal is to restore normal brain function and improve the patient's quality of life. The consistent delivery of high-dose oxygen under pressure is believed to create an environment conducive to healing and recovery at a cellular level.

Can HBOT Help with PTSD Symptoms?

Yes, hyperbaric oxygen therapy (HBOT) can help with symptoms of post-traumatic stress disorder (PTSD), according to recent research. A systematic review published in Front Neurol. 2024 specifically analyzed HBOT as a treatment for PTSD symptoms [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This review included eight studies, all with fewer than 75 subjects per study, which totaled 393 subjects. These studies showed statistically significant symptomatic improvements in patients. The subjects in these studies were diverse, ranging from 3 to 450 months post-trauma, indicating that HBOT might be beneficial both in earlier and later stages after a traumatic event.

The treatments involved 40 to 60 HBOT sessions, administered over a wide range of pressures from 1.3 to 2.0 atmospheres absolute (ATA). This suggests that HBOT can be effective across various pressure settings, providing flexibility in treatment protocols. In three of these studies, the symptomatic improvements were not just subjective; they were also associated with measurable functional and anatomic changes in brain imaging. This provides objective evidence that HBOT can influence the physical and functional aspects of the brain affected by PTSD. The study further noted a linear dose-response relationship. This means that as the cumulative oxygen dose increased, from 1002 to 11,400 atmosphere-minutes of oxygen, so did the symptomatic improvement [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This finding is crucial because it helps clinicians understand how to optimize treatment protocols for better outcomes.

Evidence from Clinical Trials

The systematic review highlighted that multiple randomized and randomized controlled clinical trials demonstrated these improvements. This type of evidence is considered high-quality in medical research. The improvements were categorized as statistically significant symptomatic improvements, Reliable Changes, or Clinically Significant Changes. These terms indicate that the observed effects were not due to chance and were meaningful for the patients' well-being. The review concluded that HBOT for PTSD is effective across a wide range of pressure and oxygen doses.

However, it is important to note the side effects. The highest doses of oxygen were associated with a severe but reversible exacerbation of emotional symptoms in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This means that while higher doses led to better overall improvement, some patients experienced a temporary worsening of their emotional state. Other side effects were generally transient and minor. This finding helps clinicians manage patient expectations and tailor treatment plans to minimize adverse reactions while maximizing benefits.

Brain Imaging and PTSD

The correlative functional and microstructural imaging changes observed in PTSD-affected brain regions are a key aspect of this research. These imaging findings suggest that PTSD might not be strictly a psychiatric disease. Instead, it could involve physical changes in the brain that respond to physiological interventions like HBOT. This perspective opens new avenues for understanding and treating PTSD, moving beyond traditional psychological approaches to include biological interventions.

As Susan R Andrews et al. stated in Front Neurol. 2024, "In multiple randomized and randomized controlled clinical trials HBOT demonstrated statistically significant symptomatic improvements, Reliable Changes, or Clinically Significant Changes in patients with PTSD symptoms or PTSD over a wide range of pressure and oxygen doses. The highest doses were associated with a severe reversible exacerbation of emotional symptoms in 30-39% of subjects. Symptomatic improvements were supported by correlative functional and microstructural imaging changes in PTSD-affected brain regions. The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease." This quote underscores the significant implications of HBOT research for redefining PTSD. The ability of HBOT to induce measurable changes in brain structure and function supports its potential as a treatment that addresses the underlying biology of the condition. For more details, see Systematic review of HBOT for PTSD.

Dosage and Response

Understanding the dose-response relationship is vital for effective treatment. The review found a linear relationship between the cumulative oxygen dose and symptomatic improvement. This means that as patients received more total oxygen over their treatment course, their symptoms tended to improve more significantly. The cumulative oxygen dose was measured in atmosphere-minutes of oxygen, ranging from 1002 to 11,400 atmosphere-minutes [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This metric helps researchers and clinicians quantify the total exposure to oxygen and relate it directly to patient outcomes.

For example, a patient receiving 60 HBOT sessions at 1.5 ATA for 60 minutes each would receive a higher cumulative oxygen dose than someone receiving fewer sessions or lower pressure. This detailed understanding of dosage allows for more precise and individualized treatment plans. It also highlights the importance of adhering to the prescribed HBOT regimen to achieve the best possible results for individuals suffering from PTSD. The careful balance between achieving therapeutic benefits and managing potential side effects, especially at higher doses, remains a critical consideration for practitioners.

How Does HBOT Affect Acute Ischaemic Stroke?

Hyperbaric oxygen therapy (HBOT) has been evaluated for its effects on acute ischaemic stroke (AIS), which occurs when blood flow to part of the brain is blocked. A systematic review and meta-analysis published in BMC Neurol. 2024 aimed to assess the efficacy and safety of HBOT as an add-on treatment for AIS [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This comprehensive analysis included eight studies, involving a total of 493 patients. The researchers compared adjunctive HBOT with non-HBOT treatments, which included no HBOT or sham HBOT.

The meta-analysis revealed mixed results regarding HBOT's impact on AIS. It showed no statistically significant differences between the HBOT group and the control group in several key outcome measures. For instance, there was no significant difference in the NIHSS score (National Institutes of Health Stroke Scale), which is a widely used tool to assess stroke severity. The mean difference (MD) for NIHSS score was -1.41, with a 95% confidence interval (CI) of -7.41 to 4.58 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. Similarly, the Barthel index, which measures a person's ability to perform daily activities, also showed no statistically significant difference (MD = 8.85, 95%CI = -5.84 to 23.54). These findings suggest that HBOT might not significantly improve overall stroke severity or functional independence as measured by these specific scales in the acute phase.

Inflammatory Markers and HBOT

The meta-analysis also examined several inflammatory markers, which are often elevated in stroke patients. These included TNF-α (tumor necrosis factor-alpha), sICAM (soluble intercellular adhesion molecule), sVCAM (soluble vascular cell adhesion molecule), sE-selectin, and CRP (C-reactive protein). For all these markers, HBOT did not show statistically significant differences compared to the control group. For example, the mean difference for TNF-α was -5.78 (95%CI = -19.93 to 8.36), and for CRP, it was -5.76 (95%CI = -15.02 to 3.51) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This indicates that HBOT might not have a strong impact on reducing systemic inflammation in the acute phase of ischaemic stroke, based on the current evidence.

However, HBOT did show some positive effects in other areas. It led to a significant improvement in the modified Rankin score (MRS), which measures the degree of disability or dependence in daily activities after a stroke. The mean difference for MRS was 0.10, with a 95% CI of 0.03 to 0.17 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. A lower MRS score indicates less disability, so this finding suggests a potential benefit of HBOT in reducing long-term disability. Furthermore, HBOT was associated with a lower incidence of adverse events at the end of treatment. The odds ratio (OR) for adverse event incidence at the end of treatment was 0.42 (95%CI = 0.19 to 0.94) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This means that patients receiving HBOT were less likely to experience adverse events during the treatment period compared to the control group.

Safety Profile of HBOT in AIS

The safety aspect is crucial for any medical intervention, especially in acute conditions like stroke. The meta-analysis found no statistically significant difference in adverse event incidence within six months of follow-up between HBOT and control groups (OR = 0.98, 95%CI = 0.25 to 3.79). This suggests that while HBOT might reduce immediate adverse events during treatment, its long-term safety profile up to six months appears comparable to non-HBOT treatments. This is an important finding, as it indicates that HBOT does not introduce significant new risks over a moderate follow-up period for AIS patients.

The overall picture for HBOT in AIS is complex. While it did not show benefits in some standard measures like NIHSS or inflammatory markers, it did demonstrate an improvement in the modified Rankin score and a reduction in adverse events during treatment. This suggests that HBOT might have specific benefits that are not captured by all outcome measures. Future research may need to explore these specific benefits further and identify which stroke patient subgroups might benefit most from HBOT. For now, the evidence suggests a cautious optimism, particularly regarding its potential to reduce disability and immediate treatment-related adverse events.

Is HBOT Being Studied for Traumatic Brain Injury?

Yes, hyperbaric oxygen therapy (HBOT) is actively being studied for its potential to help with symptoms after traumatic brain injury (TBI). One notable ongoing investigation is the Hyperbaric Oxygen Brain Injury Treatment Trial, registered as NCT02407028 on ClinicalTrials.gov [https://clinicaltrials.gov/study/NCT02407028]. This is a randomized clinical trial designed to test whether HBOT can reduce symptoms following a TBI, comparing it to an inactive (or placebo) HBOT. Such trials are crucial for establishing the true efficacy of a treatment by minimizing bias.

The University of South Florida is also involved in this research, providing further information on their HBOT program for TBI [https://hbot.usf.edu/]. Participants eligible for this trial must meet specific criteria. They need to have experienced a mild or moderate traumatic brain injury or concussion at least one year prior to enrollment. This focus on chronic TBI symptoms is important because many patients continue to suffer from persistent issues long after the initial injury. The study specifically targets U.S. Service Member Veterans and Active-Duty Military personnel, aged 18-75 years. This demographic is particularly relevant given the high incidence of TBI in military populations. The trial duration is approximately four months, allowing for a structured treatment period and follow-up to assess changes in symptoms.

Design of TBI Clinical Trials

Randomized clinical trials like NCT02407028 are considered the gold standard for evaluating medical interventions. In these trials, participants are randomly assigned to either the active treatment group (receiving HBOT) or a control group (receiving a placebo or sham treatment). This randomization helps ensure that any observed differences in outcomes between the groups are due to the treatment itself, rather than other factors. The "double-blind" aspect, as mentioned in related research [https://www.nature.com/articles/s41598-025-86631-6], means that neither the participants nor the researchers know who is receiving the active treatment. This further reduces bias and strengthens the validity of the results.

The trial aims to measure various symptoms commonly associated with TBI, such as headaches, dizziness, cognitive difficulties, and mood changes. By comparing the outcomes of the HBOT group with the control group, researchers can determine if HBOT provides a significant benefit. The trial duration of approximately four months allows for sufficient time for any potential effects of HBOT to manifest and be measured. The inclusion of veterans and active-duty military members is significant, as these individuals often face unique challenges and persistent symptoms related to TBI.

Importance of Long-Term TBI Studies

Focusing on TBI symptoms that persist at least one year after the injury is critical. Many individuals recover from acute TBI, but a substantial number experience chronic post-concussion syndrome, which can severely impact their quality of life. Traditional treatments for chronic TBI symptoms often have limited success, making the search for new therapies like HBOT highly important. If HBOT proves effective, it could offer a new treatment option for a population that currently has few. For more details, see HBOT efficacy in acute ischaemic stroke.

The research into HBOT for TBI is part of a broader effort to understand and treat complex neurological conditions. The underlying hypothesis is that increasing oxygen delivery to damaged brain tissue can promote healing, reduce inflammation, and improve neurological function. This aligns with the findings from PTSD studies, where HBOT was linked to functional and anatomical brain changes. The rigorous design of trials like NCT02407028 ensures that any conclusions drawn about HBOT's efficacy for TBI are based on robust scientific evidence. The results of such trials will be crucial in determining the future role of HBOT in managing chronic TBI symptoms.

Information for Healthcare Providers

For healthcare providers, information from trials like these is vital. Understanding the eligibility criteria, such as mild or moderate TBI exposure at least one year prior and the age range of 18-75 years, helps in identifying suitable candidates for future HBOT treatments, should the trials prove successful. The specific focus on U.S. Service Member Veterans and Active-Duty Military also highlights a particular need within this community.

The potential for HBOT to address chronic symptoms of TBI could represent a significant advancement in care. While the trial is ongoing, the systematic approach to evaluating HBOT's impact provides valuable insights into its mechanisms and potential benefits. Healthcare providers can stay informed about these developments to better counsel their patients and integrate new, evidence-based treatments into their practice as they become available. The commitment to rigorous clinical research is essential for moving HBOT from an investigational therapy to a recognized treatment for TBI.

What are the Potential Side Effects of HBOT?

Like any medical treatment, hyperbaric oxygen therapy (HBOT) carries potential side effects, although many are transient and minor. The systematic review on HBOT for PTSD highlighted specific side effects related to oxygen dosage. For PTSD treatment, the highest oxygen doses were associated with a severe, but reversible, exacerbation of emotional symptoms. This particular side effect was observed in a significant portion of subjects, specifically 30-39% [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This means that while higher doses often led to greater overall symptomatic improvement, they also carried a higher risk of temporarily worsening emotional distress for some individuals.

This temporary emotional worsening could manifest as increased anxiety, irritability, or other heightened emotional responses. The good news is that these exacerbations were reversible, meaning they did not result in permanent adverse effects. This finding is critical for clinicians to consider when determining the appropriate HBOT dosage for patients, especially those with pre-existing emotional vulnerabilities. It suggests a need for careful monitoring and potentially a gradual increase in oxygen dose to minimize the risk of these severe emotional reactions. Beyond these emotional exacerbations, other side effects noted in the PTSD studies were generally transient and minor. These might include ear discomfort or sinus pain due to pressure changes, temporary vision changes, or fatigue, which typically resolve shortly after the session.

Managing Pressure-Related Side Effects

The most common side effects of HBOT are related to the pressure changes experienced within the hyperbaric chamber. As the pressure increases, it can affect air-filled spaces in the body, such as the ears and sinuses. Patients might experience a feeling of fullness or popping in their ears, similar to what happens on an airplane. In some cases, this can lead to ear pain or even damage to the eardrum if the pressure is not equalized properly. Techniques like swallowing, yawning, or performing the Valsalva maneuver (gently blowing out through a pinched nose) are taught to patients to help equalize pressure in their ears.

Sinus pain can also occur if the sinuses are congested. It is important for patients to report any discomfort to the attending medical staff, who can then adjust the rate of pressurization or provide guidance on pressure equalization techniques. For individuals with certain medical conditions, such as severe lung disease or uncontrolled seizures, HBOT may be contraindicated due to increased risks. Therefore, a thorough medical evaluation is always performed before starting HBOT to identify any potential contraindications or risk factors.

Oxygen Toxicity

Another potential side effect, particularly at very high oxygen doses and pressures, is oxygen toxicity. This can affect the central nervous system (CNS oxygen toxicity) or the lungs (pulmonary oxygen toxicity). CNS oxygen toxicity can lead to symptoms such as visual changes, ringing in the ears, nausea, muscle twitching, irritability, dizziness, and in severe cases, seizures. Pulmonary oxygen toxicity can cause symptoms like coughing, chest pain, and shortness of breath.

However, in the context of HBOT for conditions like PTSD or TBI, the pressures and oxygen doses typically used are carefully controlled to minimize the risk of oxygen toxicity. For instance, the PTSD studies mentioned using pressures from 1.3 to 2.0 ATA, which are generally considered safe ranges when administered by trained professionals. The severe emotional exacerbations noted in 30-39% of subjects at the highest oxygen doses in PTSD studies suggest a specific sensitivity to high oxygen levels in this population, distinct from classic oxygen toxicity symptoms. This highlights the importance of individualized treatment plans and close monitoring during HBOT sessions, especially when escalating doses.

Overall Safety Profile

Despite the potential for side effects, HBOT is generally considered safe when administered by experienced medical teams in accredited facilities. The systematic review on acute ischaemic stroke (AIS) also touched upon the safety of HBOT, noting that HBOT showed a lower incidence of adverse events at the end of treatment compared to control groups (OR = 0.42, 95%CI = 0.19 to 0.94) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This suggests that for AIS, HBOT might even contribute to a safer immediate treatment experience.

It is crucial for patients to have a detailed discussion with their healthcare provider about the potential benefits and risks of HBOT, considering their specific medical history and condition. The goal is always to achieve the maximum therapeutic benefit with the lowest possible risk of adverse effects. The reversible nature of the emotional exacerbations in PTSD patients, coupled with the generally minor and transient nature of other side effects, indicates that HBOT can be safely managed when protocols are followed and patients are monitored closely.

How Does HBOT Influence Brain Function?

Hyperbaric oxygen therapy (HBOT) influences brain function primarily by increasing the amount of oxygen available to brain tissues, which can have profound effects on cellular health and neurological processes. For patients with conditions like post-traumatic stress disorder (PTSD), symptomatic improvements observed after HBOT were directly supported by changes seen in functional and microstructural brain imaging. These changes were specifically noted in brain regions affected by PTSD [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This means that HBOT isn't just alleviating symptoms; it's potentially altering the physical and functional characteristics of the brain itself. For more details, see Hyperbaric Oxygen Brain Injury Treatment Trial.

The imaging findings and the observed effects of HBOT suggest a shift in how PTSD is understood. As noted by Susan R Andrews et al., "The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease" [https://pubmed.ncbi.nlm.nih.gov/388826688/]. This implies that PTSD, traditionally viewed as purely psychological, may have underlying physiological components that respond to interventions like HBOT. The increased oxygen delivery under pressure can help reduce inflammation, promote the growth of new blood vessels, and stimulate neural repair mechanisms, all of which contribute to improved brain function. This physiological impact can lead to better cognitive processing, emotional regulation, and overall neurological health.

Mechanisms of Action in the Brain

The enhanced oxygenation provided by HBOT can support brain function through several mechanisms. First, it can help to resolve areas of hypoxia (low oxygen) in the brain that may be contributing to dysfunction. Even subtle areas of chronic low oxygen can impair neuronal function and contribute to symptoms of conditions like PTSD or traumatic brain injury (TBI). By flooding the brain with oxygen, HBOT can restore normal metabolic activity in these regions.

Second, HBOT has anti-inflammatory effects. Inflammation in the brain (neuroinflammation) is a common feature of various neurological conditions, including trauma and stroke. High concentrations of oxygen can help to reduce this inflammation, which in turn can protect neurons from damage and improve their function. This reduction in inflammation can lead to a decrease in symptoms such as brain fog, headaches, and other cognitive impairments. The body's own healing processes are also stimulated. HBOT can promote the release of growth factors and stem cells, which are crucial for tissue repair and regeneration. This regenerative potential is particularly exciting for conditions where brain tissue has been damaged, offering hope for recovery beyond symptom management.

Impact on Brain Structure and Connectivity

The observation of microstructural imaging changes in PTSD-affected brain regions is highly significant. Microstructural changes refer to alterations at a very fine level, such as changes in white matter integrity or neural connectivity. White matter acts as the brain's "wiring," connecting different brain regions. Damage or dysfunction in white matter can disrupt communication pathways, leading to a variety of neurological symptoms. If HBOT can improve these microstructural aspects, it suggests a profound impact on the brain's fundamental architecture.

Functional imaging changes, on the other hand, relate to how different parts of the brain are working and interacting. Improvements in functional imaging after HBOT indicate that brain regions are becoming more active or are communicating more effectively. This could translate to better executive function, improved memory, and enhanced emotional regulation. For example, in PTSD, areas involved in fear processing and emotional control might show altered activity. If HBOT can normalize these activity patterns, it could directly contribute to a reduction in PTSD symptoms. The ability of HBOT to induce these measurable changes strengthens the argument for its therapeutic potential in complex neurological disorders.

Reframing Neurological Disorders

The idea that PTSD may not be strictly a psychiatric disease, as suggested by the imaging findings, is a paradigm shift. It encourages a more integrated view of mental health conditions, recognizing the interplay between psychological experiences and biological processes in the brain. This perspective opens the door for physical treatments like HBOT to play a more prominent role alongside traditional psychological therapies. For example, if a patient's emotional symptoms are partly rooted in physiological brain dysfunction, then a treatment that addresses that dysfunction could be highly effective.

This reframing also has implications for other neurological conditions. If HBOT can influence brain structure and function in PTSD, it might have similar effects in other conditions characterized by brain injury or dysfunction. This could include chronic effects of stroke, traumatic brain injury, or even neurodegenerative diseases. The research into how HBOT specifically influences brain regions and neuronal networks is ongoing, but the current evidence points towards a powerful physiological mechanism at play. Understanding these mechanisms will be key to unlocking the full therapeutic potential of HBOT for a wide range of neurological challenges.

Frequently Asked Questions

What conditions is HBOT being studied for?

HBOT is being studied for a variety of conditions beyond its established uses. Recent research has focused on its potential for post-traumatic stress disorder (PTSD), acute ischaemic stroke (AIS), and traumatic brain injury (TBI). For instance, a systematic review on PTSD included eight studies involving 393 subjects, demonstrating statistically significant symptomatic improvements [https://pubmed.ncbi.nlm.nih.gov/388826688/]. There are also ongoing trials, such as NCT02407028, investigating HBOT for chronic TBI symptoms in military personnel [https://clinicaltrials.gov/study/NCT02407028].

How many subjects were in the PTSD HBOT studies?

The systematic review of HBOT for PTSD included eight studies, with each study having fewer than 75 subjects. The total number of subjects across all eight studies was 393 [https://pubmed.ncbi.nlm.nih.gov/388826688/]. These studies covered a wide range of subjects, some military and some civilian, who were 3 to 450 months post-trauma.

What kind of pressures are used in HBOT for PTSD?

For PTSD treatment, HBOT sessions were administered over a wide range of pressures. The studies analyzed in the systematic review used pressures from 1.3 to 2.0 atmospheres absolute (ATA) [https://pubmed.ncbi.nlm.nih.gov/388826688/]. Patients typically received 40 to 60 HBOT sessions, and the total oxygen dose correlated with the level of symptomatic improvement.

Are there any severe side effects of HBOT?

While HBOT is generally safe, the highest oxygen doses used in PTSD treatment were associated with a severe, but reversible, exacerbation of emotional symptoms. This occurred in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/388826688/]. Other side effects noted in these studies were typically transient and minor, such as ear discomfort from pressure changes.

Does HBOT help with acute ischaemic stroke?

For acute ischaemic stroke (AIS), a meta-analysis of eight studies involving 493 patients showed mixed results for HBOT. It did not significantly improve NIHSS scores or inflammatory markers. However, HBOT did show significant improvement in the modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17), indicating reduced disability, and a lower incidence of adverse events at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94) [https://pubmed.ncbi.nlm.nih.gov/38308217/].